MENU

Fox Chase Cancer Center News

Fleisher hopes that over the next two years her team will be able to expand and strengthen this diverse network and support emerging areas of research.
December 13, 2019

New Grant to Facilitate Health Care Disparity Research, Improve Workforce Diversity

PHILADELPHIA (December 13, 2019) –  For the past 10 years, Fox Chase Cancer Center has served as one of six regional GMaP hubs and will be able to continue and expand its role with a new $500,000 grant from the National Cancer Institute.

“Radiologists should not dismiss low density lesions of the kidney on non-contrast scans, especially if the lesion is not homogenous,” Uzzo said.
December 13, 2019

Low Density Renal Masses Should Not Be Dismissed as Benign

PHILADELPHIA (December 13, 2019) – Robert Uzzo and colleagues found that type-2 papillary renal cell carcinomas were more likely to have lower pre-contrast attenuation than type-1 tumors.

Neil Johnson and colleagues have been working to gain a better understanding of why resistance occurs.
December 11, 2019

BRCA1 Gene Rearrangements May Help Identify PARP Inhibitor Resistance

PHILADELPHIA (December 11, 2019) – New research indicates that BRCA1 gene rearrangements are responsible for generating partially active proteins that drive the development of resistance to PARP inhibitors.

The work of Sergei Grivennikov, PhD, is included in this year’s rankings by the Web of Science Group.
December 6, 2019

Fox Chase Faculty Member Recognized as Highly Cited Researcher for His Work on Immune Responses and Cancer

PHILADELPHIA (December 6, 2019) – The work of Sergei Grivennikov, PhD, is included in this year’s rankings by the Web of Science Group.

December 5, 2019

Fox Chase Cancer Center Launches New Employee Cancer Screening Initiative

To make cancer screening more convenient for staff, Fox Chase Cancer Center kicked off its Employee Cancer Screening Initiative this October.

The goal of this project is to evaluate and exploit the mechanisms of inducing programmed cell death using polyunsaturated fatty acids in triple-negative breast cancer (TNBC).
December 3, 2019

Peterson Receives Grant for Innovative Approach to Attacking Metastatic Triple-Negative Breast Cancer

PHILADELPHIA (December 3, 2019) – Fox Chase Cancer Center researcher Jeffrey Peterson, PhD, has been awarded a $1.4 million grant by the U.S. Department of Defense to evaluate and exploit the mechanisms of inducing programmed cell death using polyunsaturated fatty acids in TNBC.

December 2, 2019

Fox Chase Cancer Center Offers Tips to Reduce Your Risk for Cancer

PHILADELPHIA (December 2, 2019) – Did you know that your chances of developing cancer may be affected by your lifestyle?  According to the American Cancer Society (ACS), an estimated 42 percent of cancer cases and 45 percent of cancer deaths in the U.S. are attributed to modifiable risk factors.

November 27, 2019

Epigenetic Therapies Could Modulate EGFR Amplification, Effecting Therapeutic Response

PHILADELPHIA (November 27, 2019) – Prolonged treatment with EGFR inhibitors can reduce the copies of EGFR, leading to therapy resistance, according to Johnathan R. Whetstine, PhD. Whetstine, the study’s corresponding author.

Pages

Connect with Fox Chase